Clinical Trial to Examine the Pain Relief of PH-797804 Alone Or With Naproxen in Subjects With Osteoarthritis of the Knee

• Status: Completed
• Trial end date: 2011-03-01
• Target enrollment: 0
• Participant gender: All

Summary

PH-797804 is a potent inhibitor of inflammatory mediators that have a potential role in pain signalling following nerve injury and inflammation. Blocking such mediators may potentially have a therapeutic benefit by reducing pain.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Naproxen

Criteria

Inclusion Criteria:

• Male or female subjects between, and including, the ages of 18 and 75 years. Females must be of non-childbearing potential.

• Diagnosis of osteoarthritis of the knee based on American College of Rheumatology criteria with X-ray confirmation (a Kellgren-Lawrence X-ray grade of ≥2.

Exclusion Criteria:

• History of diseases other than osteoarthritis that may involve the index knee.

• Other severe pain that impairs the assessment of osteoarthritis of pain.

• Electrocardiogram abnormalities.

• History of gastrointestinal disorders.